Vita, Antonio
Fagiolini, Andrea
Maina, Giuseppe
Mencacci, Claudio
Spina, Edoardo
Galderisi, Silvana
Article History
Received: 29 November 2022
Accepted: 29 December 2022
First Online: 17 January 2023
Declarations
:
: Not applicable.
: All the authors concur with the submission and have approved the final manuscript.
: A. Vita has received directly or indirectly support for clinical studies or trials, conferences, consultancies, congress presentations, advisory boards from: Angelini, Boheringer Ingelheim, Eli Lilly, Fidia, Forum Pharmaceutical, Innovapharma, Janssen-Cilag, Lundbeck, Otsuka, Rovi, Recordati, and Takeda. A. Fagiolini is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Doc Generici, Glaxo Smith Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Rovi, Sanofi Aventis, Sunovion, and Vifor. G. Maina has received grants from Compagnia San Paolo Foundation, Lundbeck Italia and honoraria/advisory board from Angelini, Boheringer, Biohavenpharma, Fidia, GSK, Janssen, Lundbeck, Mylan, Otsuka, Recordati, Rovi, and Sanofi. C. Mencacci has received honoraria as speaker/webinar/symposium from Fidia, Lundbeck, Janssen, Italfarmaco, Valeas and from Rovi for Advisory Board. E. Spina has participated in speakers/advisory boards and received support from Angelini, ArcaPharma, Janssen Pharmaceuticals, Lundbeck, Otsuka and Rovi. S. Galderisi has received honoraria from Angelini, Gedeon Richter-Recordati, Janssen Australia and New Zealand, Janssen Pharmaceutica NV, Janssen Cilag, Lundbeck AS, Lundbeck Italia, Recordati, and Sunovion, and has participated in advisory boards for Angelini, Gedeon Richter, Innova Pharma-Recordati Group, Janssen Pharmaceutica NV and Rovi.